Peptic Ulcer Clinical Trial
Official title:
Bleeding Ulcer and Erosions Study "BLUE Study"
A prospective study of bleeding peptic ulcers and/or erosions in the upper gastrointestinal tract - risk-medication, presence of Helicobacter pylori, treatment and outcome.
Patients admitted to hospital due to hematemesis and/or melena with endoscopic finding of
ulcer and/or erosion in the ventricle and/or duodenum are eligible for inclusion in the BLUE
study after an informed consent has been obtained. The gastroscopy must be performed within
72 hours after admission. Epidemiological data, comorbidity and past clinical history are
recorded in addition to the consumption of defined risk medication and proton-pump inhibitors
(PPI) during the last 4 weeks.
The Forrest classification is used to describe an ulcer if present at endoscopy and
endoscopic modalities for treatment are used according to established recommendations.
Surgery or radiological intervention will be applied if needed.
An infection with H. Pylori is diagnosed by different methods including a rapid urease test,
culture and serology. If one of these tests is positive, the patient will receive triple
therapy. To secure successful eradication patients are tested with 13C UBT (breath test) or
HP antigen stool test after 3 months and HP IgG serology after 6 months.
Registration of lowest haemoglobin (Hb) level during hospitalization and an algorithm to
treatment with blood transfusion and/or high dose IV iron will be performed to evaluate
alternative treatments to blood transfusions alone. Effect of treatment is evaluated at 8
weeks and 6 months. A follow-up gastroscopy and blood test is performed after 2-3 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00471029 -
Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer
|
Phase 4 | |
Completed |
NCT00152399 -
Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
|
Phase 2 | |
Not yet recruiting |
NCT02961296 -
Helicobacter Pylori Antibiotic Susceptibility Testing of Korea
|
N/A | |
Completed |
NCT00212225 -
Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)
|
N/A | |
Completed |
NCT02342470 -
Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users
|
Phase 2 | |
Completed |
NCT02296021 -
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Completed |
NCT00977678 -
Drop in Gastroscopy - Experience After 9 Months
|
N/A | |
Terminated |
NCT04025983 -
Effectiveness of GastimunHp Plus in Supporting the Treatment of Peptic Ulcer Disease With Helicobacter Pylori Infection
|
N/A | |
Recruiting |
NCT03868267 -
Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
|
||
Completed |
NCT05237115 -
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Completed |
NCT01667718 -
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
|
Phase 4 | |
Not yet recruiting |
NCT04784910 -
Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer
|
Phase 3 | |
Recruiting |
NCT02436018 -
WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy
|
N/A | |
Active, not recruiting |
NCT02001727 -
HEP-FYN 12-Years Follow-up
|
N/A | |
Completed |
NCT01376414 -
H. Pylori Testing for Patients With Non-specific Upper Abdominal Pain in the Emergency Department
|
N/A | |
Completed |
NCT01667692 -
Aizthromycin or Clarithromycin in H-pylori Eradication Regimen
|
Phase 4 | |
Completed |
NCT01080326 -
Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus
|
N/A | |
Completed |
NCT02536989 -
Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot
|
Phase 4 | |
Completed |
NCT00920400 -
Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract
|
N/A | |
Completed |
NCT00450658 -
Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers
|
Phase 3 |